The all-in-one platform to find and track your stocks and investments
Discover the features
Statistics
Market Cap
300 billion
PE Ratio
59.14 x
Beta (volatility)
0.61
Earnings Per Share
2.79
About
ISIN : US00287Y1091
discovers, develops, manufactures, and sells pharmaceuticals in the worldwide.
The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque...
Price
Performance Comparison
| AbbVie Inc | |
|---|---|
| 1 year return |
+24 %
|
| 5 years return |
+131 %
|
Valuation
| Price to Book | Payout ratio | PEG Ratio |
|---|---|---|
| 48.34 | 58 % | 0.39 |
| Price to Sales | Price / FCF | E.V.R. |
|---|---|---|
| 5.52 | 13.25 | 6.40 |
Price–Earnings Ratio History
For this company, we show you a quick help in graphical form that tells you if the stock looks overvalued, undervalued or fairly priced, and by how much. Stop paying too much for your shares.
Unlock valuation chart for this company
Dividend History
Uninter. Dividend
11 years
Frequency
4x / year
Dividends in 2023
February, May, August, November
Dividends in 2022
February, May, August, November
February, May, August, November
Dividends in 2022
February, May, August, November
Forward Annual Amount
$6.56
Ex-dividend
1/15/2025
Number of Outstanding Shares
Sales segmentation
Financials
Year-over-Year growth
Profitability
Health
News
Earnings report announcement
10/30/2024
AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps.
11/11/2024
AbbVie Stock Slides on Schizophrenia Drug Study Failure
11/11/2024
Eli Lilly's Zepbound sales, Pfizer wants in on weight loss drugs, AbbVie's big deal: Pharma news round up
11/1/2024
AbbVie Has A New Cash Cow As Humira Bows To Skyrizi In Third-Quarter Beat
10/30/2024
AbbVie Stock Rises After Earnings Beat, Dividend Hike
10/30/2024
AbbVie is buying an Alzheimer's drug for more than $1 billion
10/28/2024
Nine Provinces Approve Accelerated Public Reimbursement of Diffuse Large B-Cell Lymphoma Treatment Under New Early Access Process
10/21/2024
Allergan’s BOTOX Cosmetic gets FDA approval in jaw-neck bands
10/20/2024
BOTOX® Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands)
10/18/2024
AbbVie (ABBV): Growth Driven by Skyrizi, Rinvoq, and Strategic Acquisitions
10/18/2024
Pharma Stock Roundup: JNJ's Q3 Earnings, FDA Nod to Some New Drugs
10/18/2024
The Zacks Analyst Blog Highlights AbbVie, Automatic Data Processing, Analog Devices, Taylor Devices and Village Super Market
10/18/2024
Create a portfolio & add this stock
Add this stock and others to your own virtual portfolio and get personalised information : total annual dividends & total value, sectors breakdown, etc.
Privacy Policy • Terms and Conditions
© Copyright 2020-2024 Epsylia OÜ - All rights reserved
Moning is a platform that does not manage any funds and is purely educational. We do not provide any investment advice.
The data presented comes from different providers and may contain errors. We encourage you to always verify information through other sources.
Any financial investment involves risks including partial or total loss of capital.
The data presented comes from different providers and may contain errors. We encourage you to always verify information through other sources.
Any financial investment involves risks including partial or total loss of capital.